TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven diagnosis of non-small cell lung cancer~* positive for the ALK fusion gene (test provided by a central laboratory)~* must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug~* tumors must be measurable~Exclusion Criteria:~* prior treatment with PF-02341066~* current treatment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-02341066 (Type: EXPERIMENTAL): None
- Pemetrexed or Docetaxel (Type: ACTIVE_COMPARATOR): Investigator selection of either pemetrexed or docetaxel as the active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects who received cholic acid through CCHMC protocols 91-10-10 or CAC-002-01 and meet the following criteria are eligible for study participation.~1. The subject and/or parent/legal guardian must have provided informed consent prior to study start.~2. The subject must have a diagnosis of an inborn error of bile acid synthesis.~3. The subject must be willing and able to comply with all study assessments and procedures.~4. Subjects with other organ dysfunction will not be excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholic Acid (Type: OTHER): Active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fostamatinib for Hospitalized Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Patient must be hospitalized, or had their inpatient stay extended, for COVID-19.~ 2. Age \>=18 years~ 3. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~ 4. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.~ 5. Females of childbearing potential must agree to be abstinent or use a medical acceptable form of contraception from the time of enrollment through 30 days after last day of study drug~ 6. Laboratory confirmed SARS-CoV-2 RT-PCR test within 7 days of enrollment~ 7. Illness of any duration with SpO2 of less than 94% on room air requiring supplemental oxygen via nasal canula or non-invasive mechanical ventilation, or mechanical ventilation or ECMO (5 to 7 on the 8-point scale)~EXCLUSION CRITERIA:~1. ALT or AST \> 5 times the upper limit of normal (ULN) or ALT or AST \>= 3 x ULN and total bilirubin \> 2 x ULN.~2. Estimated glomerular filtration rate (eGFR) \<30ml/min~3. Pregnancy or breast feeding~4. Anticipated discharge in the next 72 hours~5. Allergy to study medication~6. Uncontrolled hypertension (systolic blood pressure \>160mmHg or diastolic blood pressure \>100mmHg)~7. Shock or hypotension at the time of enrollment~8. Neutrophil count \<1000/microliter~9. Concern for bacterial or fungal sepsis~10. Received immunomodulatory treatment within 30 days prior to enrollment e.g., Bruton's tyrosine kinase/phosphoinositide 3 kinase/Janus kinase inhibitor or cytokine-targeting biologic therapy (anti-TNF, IL-6)~11. Received a live vaccine the last 4 weeks~12. Those who were cognitively impaired or mentally disabled prior to COVID diagnosis~13. Participation in another clinical trial for the treatment of COVID-19.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
- Intervention - Placebo (Type: PLACEBO_COMPARATOR): Placebo in combination with standard of care (SOC) for the treatment of COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Center Food Allergy Oral Immunotherapy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic subjects between the ages of 4 to 55 years old.~* Sensitivity to food allergen will be documented by a positive skin prick test result (see Appendix for details) or allergen specific ImmunoCAP IgE level with 7 kU/L as a lower limit of eligibility.~Exclusion Criteria:~* No absolute contraindications are known. However, the risk of serious systemic anaphylactic reactions to food allergens suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers).~* Subjects having a history of severe anaphylaxis to food allergens that will be desensitized in this study requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- One (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: P3 (Prepared, Protected, emPowered)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are aged 16-24~* Were assigned male sex at birth~* Report sex with men or transgender women~* Are able to speak and read English~* Have reliable daily access to an Android or iOS smartphone with a data plan~* Are HIV-uninfected (self-report)~* Are not currently on PrEP but plan to initiate in the next 7 days and have an active PrEP prescription (prescription confirmed by study staff) OR on PrEP have an active PrEP prescription (prescription confirmed by study staff)~* Recruited from one of 9 subject recruitment venues (SRV) cities (Atlanta, Georgia; Boston, Massachusetts; Bronx, New York; Chicago, Illinois; Houston, Texas; Philadelphia, Pennsylvania; Tampa, Florida; Chapel Hill, NC; Charlotte, NC)~Exclusion Criteria:~* Aged younger than 15 years or older than 24 years~* Not available to meet with project staff for planned study visit(s)~* Non-English speaking~* Living with HIV~* Not currently prescribed PrEP (study staff unable to verify participant has an active PrEP prescription by a health provider)~* Anticipate not having reliable access to a smartphone with a data plan for 2 or more days during field testing or 1 or more weeks during the RCT intervention period~* Planning to move out of study area during the study period~* Unwilling or unable to comply with protocol requirements.~* Participated in field trial phase of P3 study~* Unable to be consented due to active substance use or psychological condition.

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- P3 (Type: EXPERIMENTAL): Participants will use P3
- P3+ (Type: EXPERIMENTAL): Participants will use P3+
- Control (Type: PLACEBO_COMPARATOR): Participants will receive the standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NIRS Monitoring to Detect AKI in Preterm Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants \< 32 weeks~* Admitted to Unity Point Health(UPH) Meriter Newborn Intensive Care Unit (NICU)~* Application of NIRS by 48 hours of age~Exclusion Criteria:~* Congenital anomaly of the kidney or urinary tract (CAKUT)

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- NIRS monitoring (Type: None): These infants will be monitored with NIRS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Given their signed written informed consent to participate. Must have agreed to participate in and complete the lead-in Study PT010006.(NCT02497001)~Exclusion Criteria:~Severe osteoporosis Unable to achieve an acceptable DEXA scan Inability to achieve pupil dilation to at least 6 mm Subjects with an implanted artificial intraocular lens or are scheduled to undergo cataract surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BGF MDI (PT010) 320/14.4/9.6 μg (Type: EXPERIMENTAL): Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
- GFF MDI (PT003) 14.4/9.6 μg (Type: EXPERIMENTAL): Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
- BFF MDI (PT009) 320/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Positive HBsAg \>= 6 months prior to randomization and positive HBeAg at screening.~* Serum HBV DNA greater than or equal to 1 x 100,000 copies/mL (PCR assay) at initial or confirmatory screening visit.~* Serum ALT levels greater than or equal to 1.5 x ULN at both initial and confirmatory screening visits.~* Compensated liver disease with anticipated survival greater than 12 months and with the following laboratory and clinical parameters within 4 weeks of baseline: \*Prothrombin time less than or equal to 1 second above normal range. \*Total bilirubin less than 1.3 mg/dL or normal direct bilirubin. \*Serum albumin greater than 3 g/dL (greater than 30 g/L). \*No clinical history of ascites, variceal bleeding, encephalopathy or splenomegaly. \*Adequate renal function defined as creatinine clearance greater than or equal to 80 mL/min (calculated using Schwartz Formula).~Key Exclusion Criteria:~* Received immunoglobulin, interferon or lamivudine therapy within 6 months prior to initial screening visit.~* Participated in any investigational trial with any investigational compound within 2 months prior to initial screening.~* Organ or bone marrow transplant recipients.~* Clinical evidence of decompensated liver disease.~* A Child-Pugh-Turcotte score greater than 6.~* Inability to comply with study requirements.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (PLB) (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
- Adefovir Dipivoxil (ADV) (Type: EXPERIMENTAL): Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C, genotype 1 infection with interleukin 28B (IL28B) rs12979860 genotype C/C.~* Liver biopsy within 3 years with histology consistent with hepatitis C virus (HCV) - induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV.~* Treatment naïve male or female between the ages of 18 and 65.~* Females must be postmenopausal for at least 2 years or surgically sterile.~* Be in a condition of general good health, as perceived by the investigator, other than hepatitis C virus infection.~* Body mass index 18 to \< 35 kg/m\^2 .~Exclusion Criteria:~* Significant sensitivity to any drug.~* Use of herbal supplements within 2 weeks prior to study drug dosing.~* Positive screen for certain drugs or alcohol.~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibody.~* Use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1 month of dosing.~* Prior treatment with any investigational or commercially available anti-hepatitis C virus agents.~* Abnormal laboratory tests.~* Cirrhosis or extensive bridging fibrosis.~* History of cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r and ABT-072, plus ribavirin (RBV) (Type: EXPERIMENTAL): ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tigecycline for Treatment of Rapidly Growing Mycobacteria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive cultures for rapidly growing mycobacteria~* Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs~* Adults and children 10 years of age and older~* Pretreatment isolate of M. avium complex available for MIC determination~* Available for followup appointments~Exclusion Criteria:~* History of tetracycline allergy~* If a menstruating female, not pregnant and on adequate birth control

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tigecycline (Type: EXPERIMENTAL): tigecycline titrated dose according to patient age and clinical status

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Given written informed consent~* Male or female aged ≥ 19~* Primary immune thrombocytopenia (ITP)~* Platelet \<20x10\^9 /L~* Patients who have taken adrenal cortical hormones and/or other immunosuppressive medications should maintain their stable doses before and during this study~Exclusion Criteria:~* Patients who have participate in other interventional study within 30 days~* Inability in written/verbal communication~* Engaged with an elective surgery~* Pregnant or breast-feeding women~* Women of childbearing potential who do not agree with contraception during this study~* Patients who had experienced any hypersensitivity or shock with study drug or active ingredient~* Refractory to immunoglobulin therapy~* Secondary immune thrombocytopenia~  * HIV-associated ITP~ * Lupus-associated ITP~ * Lymphproliferative disease~ * Hepatitis virus carrier~ * Other disease- or infection-associated ITP~* Drug-Induced ITP~* Hereditary thrombopenia (e.g., MYH9 disorders)~* Hemolytic anemia (Positive direct Coomb's test)~* Clinically significant abnormalities of immunoglobulin~* Immunoglobulin A Deficiency~* Immune disorders or deficiency~* Alcohol or drug abuse within 6 months~* Patients who had taken any medications which may effect platelet function or count for at least 2 days prior study entry~* Patients who had administrated with IVIg or anti-D immunoglobulin agents within 1 month~* Patients who had undergone a splenectomy within 2 months~* Clinically significant underlying disease or medical history at investigator's discretion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human immunoglobulin intravenous (Type: EXPERIMENTAL): Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAX 326 (rFIX) Continuation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Subject and/or legal representative has/have voluntarily provided signed informed consent~* Subject has completed Baxter clinical study 250901 (pivotal study) or Baxter clinical study 251101 (pediatric study)~* Subject was 12 to 65 years old at the time of screening for Study 250901 or \< 12 years old at the time of screening for Study 251101~* Subject has severe (FIX level \< 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory~* Subject has not developed an inhibitory FIX antibody during Baxter Pivotal Study 250901 or Pediatric Study 251101~Main Exclusion Criteria:~* Subject received factor IX product(s) other than BAX 326 upon completion of Baxter Pivotal Study 250901 or Pediatric Study 251101~* Subject has been diagnosed with an acquired hemostatic defect other than hemophilia B~* For subjects transferring from Pivotal Study 250901: Subject's weight is \< 35 kg or \> 120 kg~* Subject is planned to take part in any other clinical study, with the exception of BAX 326 Surgery study as described in this protocol, during the course of the Continuation Study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAX 326 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapse of Clostridium difficile infection with previous trial of vancomycin or fidaxomicin~Exclusion Criteria:~1. Pregnancy or breastfeeding~2. Does not speak or understand the Danish language~3. Current antibiotic treatment other than metronidazole, vancomycin, fidaxomicin~4. fulminant colitis which contraindicates medical treatment~5. physician's evaluation that the patient cannot tolerate project inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- FMT (Type: EXPERIMENTAL): Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
- Fidaxomicin (Type: ACTIVE_COMPARATOR): 10 days fidaxomicin 200 mg x 2 daily
- Vancomycin (Type: ACTIVE_COMPARATOR): 10 days vancomycin 125 x 4 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete